# Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

> **NCT04935229** · PHASE1 · TERMINATED · sponsor: **TriSalus Life Sciences, Inc.** · enrollment: 67 (actual)

## Conditions studied

- Metastatic Uveal Melanoma in the Liver

## Interventions

- **DRUG:** SD-101
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab and Relatlimab

## Key facts

- **NCT ID:** NCT04935229
- **Lead sponsor:** TriSalus Life Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-02
- **Primary completion:** 2024-07-17
- **Final completion:** 2024-07-17
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** The decision was made to terminate the study after the completion of Phase 1 enrollment and not proceed with Phase 2. Trial termination was not due to patient safety or data concerns.
- **Last updated:** 2025-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04935229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04935229, "Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04935229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*